'GP said my daughter was faking it - a week later she was diagnosed'
Prior to this, Summer, from Hampshire, had been "constantly poorly" and bruising easily. However, when Rebecca, 33, took her ...
GP accused daughter, 4, of ‘faking it’ and said to ‘dose her up on Calpol’ before ...
A MUM is urging parents to trust their “instincts” after claiming her GP said her four-year-old daughter was “faking” ...
pharmaphorum3 小时
Autolus bags FDA approval for leukaemia cell therapy
Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...
The American Journal of Managed Care3 天
Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia
A case report suggests vigilance is required even when cancers like acute lymphoblastic leukemia appear to go into remission without explanation. Adding blinatumomab to consolidation chemotherapy ...
Mum claims GP said daughter, 4, was 'faking it' before terrible diagnosis
A mum who claims her GP said her four year-old daughter was 'faking it' a week before she was diagnosed with blood cancer is ...
The American Journal of Managed Care2 天
FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia
Obecabtagene autoleucel (obe-cel; Aucatzyl) has been approved by the FDA to treat patients with relapsed or refractory B-cell ...
Newcastle University10 天
Acute lymphoblastic leukaemia
A groundbreaking study has uncovered molecular markers in blood at birth that are linked to later development of acute ...
Syncona : Autolus Receives FDA Approval For AUCATZYL In Adults With Relapsed/Refractory B-ALL
Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...
Targeted Oncology6 天
Optimizing Transplant Timing in Acute Lymphoblastic Leukemia
Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.
Cure Today2 天
FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...
London South East4 小时
Syncona's Autolus wins FDA approval for aggressive leukaemia therapy
The life science investor said investee, Autolus Therapeutics - a biopharmaceutical company specialising in next-generation programmed T cell therapies - has received FDA marketing approval for ...